1. Home
  2. ANAB vs CSR Comparison

ANAB vs CSR Comparison

Compare ANAB & CSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$63.15

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo D/B/A Centerspace

CSR

D/B/A Centerspace

HOLD

Current Price

$57.00

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
CSR
Founded
2005
1970
Country
United States
United States
Employees
N/A
349
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
ANAB
CSR
Price
$63.15
$57.00
Analyst Decision
Buy
Hold
Analyst Count
12
6
Target Price
$71.67
$69.80
AVG Volume (30 Days)
485.4K
185.4K
Earning Date
05-08-2026
05-04-2026
Dividend Yield
N/A
4.58%
EPS Growth
91.02
N/A
EPS
N/A
N/A
Revenue
$234,603,000.00
N/A
Revenue This Year
N/A
$1.24
Revenue Next Year
$52.14
$2.72
P/E Ratio
N/A
$62.27
Revenue Growth
157.01
N/A
52 Week Low
$17.11
$52.76
52 Week High
$73.30
$69.61

Technical Indicators

Market Signals
Indicator
ANAB
CSR
Relative Strength Index (RSI) 59.71 38.79
Support Level $52.32 $57.05
Resistance Level $67.69 $60.30
Average True Range (ATR) 3.05 1.79
MACD 0.99 0.14
Stochastic Oscillator 93.72 53.58

Price Performance

Historical Comparison
ANAB
CSR

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About CSR D/B/A Centerspace

Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.

Share on Social Networks: